Alexion Pharmaceuticals Finance Intern in Ireland

Intern (Global Operations Finance)

Reports to:

Location:

Alexion, Dublin

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.

Position Summary

The Global Operations Finance Intern will be a key member of Alexion’s Global Operations Finance team, and will be based in Dublin. This role will support expanding global operations, with a unique opportunity to lead and be involved in projects during a key time in the manufacturing operations startup.

Alexion is a high growth bio-pharmaceutical company with operations in over 40 countries worldwide. As Alexion has grown in size and geography, the manufacturing operations have also expanded globally, requiring focused expertise in our Global Manufacturing Operations headquarters in Dublin, Ireland.

This role provided the opportunity to interaction and learn from operations and finance teams and the successful individual will need to be a self-starter in a very dynamic environment.

Principal Responsibilities

  • Assist in month end close process including account analysis & reconciliation, preparing inputs to month end reports including financial analysis & commentary

  • Prepare balance sheet account reconciliations and follow up & resolve reconciling items in a timely manner

  • Support variance analysis of financial results for month end reporting purposes

  • Assist with ad hoc financial analysis and queries

  • Participate in various finance related projects

  • Support with local statutory and tax requirements

  • Support the Accounting team with SOX related activities

  • Ensure the accurate compilation, analysis and reporting of accounting data

Skills

  • Microsoft Office Excel proficiency

  • Strong numeracy skills with focus on attention to detail

  • Strong verbal and written communication skills

  • Excellent academic track record

Education

  • Business/Accounting undergraduate desirable

[[filter5]], [[filter1]]

[[filter4]]

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas.